 | |
- close
- close
FierceBiotech
6 hrs ago
Comment
In the course of reporting its fourth quarter earnings, Dutch biotech Crucell said that it plans to boost R&D spending by a third in 2010. That's following a big year in 2009, during which the company landed a $70 million contract with NIAID/NIH...
Reuters
Feb 9
Comment
Dutch biotech Crucell reported a better-than-expected 18 percent fall in fourth-quarter net profit on Tuesday and said 2010 revenues and other operating income will be broadly in line with 2009.
Marketwire
Feb 9
Comment
LEIDEN, NETHERLANDS -- (Marketwire) -- 02/09/10 -- Crucell Announces Record Revenues and Profits for Full Year 2009 Total revenues and other operating income increased 26% to EUR358.0 million. Operating profit increased more than four-fold to EUR39.0
Marketwire
Feb 2
Comment
LEIDEN, NETHERLANDS -- (Marketwire) -- 02/02/10 -- Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it will release its financial results for the fourth quarter and the full year
Bloomberg
Jan 29
Comment
Bill and Melinda Gates said their
foundation will commit $10 billion over the next decade to help
develop vaccines for the world’s poorest countries, a project
that may save the lives of 8.7 million children.
Crucell launches global brand to reflect and reinforce its leading position in healthcare innovation
Marketwire
Nov 16
Comment
LEIDEN, NETHERLANDS -- (Marketwire) -- 11/16/09 -- Global biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL) (SWISS: CRX) today announced the launch of the global Crucell brand, a consistent identity for its worldwide activities and
newratings.com
Nov 6
Comment
NEW YORK, November 5 (newratings.com) - Analysts at UBS upgrade Crucell N.V. (ticker: CRXL) from "neutral" to "buy." [more]
StreetInsider.com
Nov 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/UBS+Upgrades+Crucell+NV+%28CRXL%29+to+Buy+/5078303.html for the full story.
Globe Newswire
Nov 5
Comment
BELLEVUE, Wash., Nov. 5, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell N.V.
Globe Newswire
Nov 4
Comment
BELLEVUE, Wash., Nov. 4, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell N.V.
Suggest other news sources for this topic
Thank you for your suggestion
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| ||||||
